Cardiovascular Prevention and Pharmacotherapy

Review Article

Challenges and Future in Precision Cardiovascular Medicine: Sang Hong Baek; Cardiovasc Prev Pharmacother. 2019;1(1):10-18. Published online July 31, 2019; DOI: https://doi.org/10.36011/cpp.2019.1.e3

4,746 View
21 Download
2 Citations

Cardiovascular disease (CVD) still remains the global leading cause of mortality and also impose major burdens on morbidity, quality of life, and societal costs despite of the remarkable progress of cardiovascular (CV) treatment over the past 50 years. CVD therapy improves CV outcomes in less than half of patients. Precision medicine is an attractive and advancing strategy to enhance for disease prevention, diagnosis, and tailored treatment and allocate limited resources more wisely and effectively. We are now in the middle of fourth industrial revolution by a robust confluence of biotechnology, physical science and information technologies. This approach is in its premature so far, but has begun to yield useful information that moves from the conventional ‘average response’ approach to more specific and targeted approaches governed by individual variability. This review aims to how precision medicine, genomics, and epigenetics work together to create a new era of CV precision medicine.

Citations

Citations to this article as recorded by

Cell-free DNA in maternal blood and artificial intelligence: accurate prenatal detection of fetal congenital heart defects
Ray Bahado-Singh, Perry Friedman, Ciara Talbot, Buket Aydas, Siddesh Southekal, Nitish K. Mishra, Chittibabu Guda, Ali Yilmaz, Uppala Radhakrishna, Sangeetha Vishweswaraiah
American Journal of Obstetrics and Gynecology.2023; 228(1): 76.e1. CrossRef
Welcome to the New JournalCardiovascular Prevention and Pharmacotherapy
Mi-Jeong Kim, Jang-Whan Bae, Dae Ryong Kang
Cardiovascular Prevention and Pharmacotherapy.2019; 1(1): 1. CrossRef

First
Prev
Page of 1
Next
Last

Search